Introduction
The public conversation around GLP-1 medications has created a new kind of scrutiny. People are judged for using treatment, judged for not using it, and often left to handle the emotional side of weight loss with very little support. This article argues that Ozempic shame is becoming a new form of diet culture, and that patients need education, privacy, and practical daily support alongside prescription care.
The conversations around the "wonder drug" movement
"She's probably on weight-loss drugs. He probably needs them. There's no way they lost all that weight without them." We've all been party to the conversations around the weight-loss "wonder drug" movement.
Underpinning it all is a darker theme: is "Ozempic shaming" the new diet culture, where patients cannot win, and societal judgement is creating a new wave of internalised guilt and body image trauma?
To many, using prescription drugs to support your weight-loss journey feels like "cheating." Despite obesity being recognised as a chronic disease, patients are often derided for a lack of discipline, accused of leaning into a new fad crash diet, or pushed on whether they have thought about the long-term impact or issues they face. The constant public scrutiny of celebrities like Serena Williams who have achieved noticeable weight loss does not help.
Wave after wave of research notes the wider positive impact of using these medications on prescription. Improved blood pressure and lower risk of heart attacks, better kidney function, and support for conditions such as Polycystic Ovary Syndrome all sit in the wider clinical conversation. Some research is even exploring whether these medicines could help treat alcohol use disorder. In many ways, as a treatment programme, it is not too far removed from taking statins for heart disease.
The emotional side is still overlooked
Even in a world where awareness of mental health issues is improving, the emotional side of GLP-1 treatment is sorely overlooked. Clinical trials do not capture what it actually feels like. Many people hide their GLP-1 use, which creates isolation right when they need support most.
The internal dialogue does not stop: "Is this cheating? What happens when I stop?" A prescriber often has barely fifteen minutes with a patient every few months. The emotional side of this process needs daily support.
Dr Danna Kashlan, Founding Medical Adviser at Lina, said: "There's this idea that using a GLP-1 is 'cheating,' and it's completely backwards. We don't tell patients with hypertension or asthma they're cheating for taking medication, but with obesity, we shame people into believing it's all willpower."
She added: "Obesity is a chronic, multifactorial disease influenced by genetics, biology, environment, and behavior. So when people say it's 'cheating,' the real question is, cheating what, exactly? Their biology?"
What Dr Kashlan sees clinically is that these medications give patients, often for the first time, a sense of control and understanding around hunger and satiety. But without education and support, patients are left navigating major physical and emotional changes alone, and that is where shame starts to build.
Shame can follow success too
In some cases, users have reported a blunting of their reward response: reduced interest in things that previously gave them pleasure, or dulled emotions. Weight loss treatments do not automatically address the emotional triggers that can lead to overeating, and failure to adhere to plans as a result can perpetuate a shame cycle that drives real emotional turmoil.
Even when a patient is achieving the exact results they wanted, drastic changes in the body can still lead to self-consciousness and a feeling of being uncomfortable in your own skin. Such a dramatic change in habits, how you feel physically, and your own thoughts about how you may be perceived can cause stress on a daily basis.
The potential risks around the emotional side of treatment are not being completely overlooked by academics. Michael Stanton PhD, a professor of public health at California State University, has warned that we need to be careful not to create a new problem with these medicines, because focusing on medication without addressing systemic causes of obesity may reinforce weight stigma.
He is right. Patients need increased support throughout the process to help do the internal work that will turn new behaviours into habits for life, and to celebrate the non-scale victories that bring mental benefits alongside visible changes: increased energy, better sleep, confidence, and more.
The next step is identity, not just weight loss
At some point, you stop saying "I'm trying to be healthier" and start saying "I take care of my health." That shift comes from repeated action, not affirmation. What you do every day becomes who you are.
Integrating support that helps that shift into weight loss management is the crucial next step in making these medications work better for the people taking them. The prescription can create an opening. What happens inside that opening depends on education, support, privacy, and the small daily behaviours that help someone feel less alone.
What better support should look like
Better support does not mean replacing the clinician or turning every emotion into a medical problem. It means giving patients a private place to notice what is changing, ask better questions, and build routines that make treatment feel less lonely. A useful support system should help people record how they are feeling, understand what side effects or appetite changes are doing to daily life, and prepare for appointments without shame or panic.
It should also make room for the parts of progress that are easy to dismiss because they do not fit a before-and-after photo. Sleeping better, walking further, eating with less fear, drinking enough water, feeling able to plan a week, or being honest with a clinician are all meaningful signals. When the public conversation only rewards visible weight loss, patients can miss the quieter evidence that their relationship with health is changing.
The goal is not to make GLP-1 treatment look effortless. It is to make it supported. Medication can change hunger and satiety, but people still need help with identity, habits, uncertainty, and the social pressure that follows visible change. If we ignore that, we risk replacing one form of judgement with another.
